UCLA Scientists Develop One-Product-Fits-All Immunotherapy for Pancreatic Cancer
November 25, 2025
November 25, 2025
LOS ANGELES, California, Nov. 25 (TNSjou) -- The UCLA Health issued the following news release:
* * *
UCLA scientists develop one-product-fits-all immunotherapy for pancreatic cancer
Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers around 2-3%, and median survival is often measured in months rather than year . . .
* * *
UCLA scientists develop one-product-fits-all immunotherapy for pancreatic cancer
Pancreatic cancer is among the deadliest forms of cancer, with most patients diagnosed after the disease has already spread throughout the body. The five-year survival rate for metastatic cases hovers around 2-3%, and median survival is often measured in months rather than year . . .